Apr 23, 2021 · Background Thalidomide is an immunomodulatory agent with a spectrum of activity that is only partly characterized. Originally introduced as a nonbarbiturate hypnotic, it was …

Apr 23, 2021 · Lenalidomide is structurally similar to thalidomide, and as such is considered a teratogen with the potential to cause birth defects and fetal death. Lenalidomide is being …

Phase 2 NIC5-15 Phase 2 Neflamapimod Phase 2 Nelonicline Phase 2 ORM-12741 Phase 2 PF-05212377 Phase 2 Pioglitazone Phase 2, Phase 3 Piromelatine Phase 2 Relyvrio Phase 2 …

Nov 25, 2015 · AD Target / Therapy Types The two tables below organize the therapeutics within this database by therapy type and proposed target type. The number of therapeutics within …

NSC001 AAB-003 AADvac1 AAV-GAD AAV2-BDNF ABBV-1088 ABBV-552 ABBV-916 ABT 418 ABT-089 ABT-288 ABT-384 ABT-957 ABvac40 ACD856 Acetyl-l-carnitine HCI ACI-24.060 …

Study aborted Inflammation 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 ALZT-OP1 …

Jan 5, 2018 · Because the immunomodulatory drug thalidomide is known to inhibit TNF signaling, Shen and colleagues tested thalidomide’s effects in mice, and confirmed that it reduced Aβ …

May 3, 2023 · When the scientists conjugated this sdAb to thalidomide to bind E3 ubiquitin ligase and trigger degradation of the complex, the treatment nearly eliminated aggregated α-synuclein.

NSC001 AAB-003 AADvac1 AAV-GAD AAV2-BDNF ABBV-0805 ABBV-552 ABBV-916 ABBV-CLS-7262 ABT 418 ABT-089 ABT-288 ABT-384 ABT-957 ABvac40 ACD856 Acetyl-l-carnitine …

Amyloid-Related Small Molecule Alzheimer's Disease41 Therapeutics View Results Reset